Form 4: Quest Diagnostics SVP Plans Stock Sale

Quest Diagnostics' SVP of Diagnostic Services, Patrick Plewman, plans to sell 1,975 shares of common stock on August 15, 2025, under a Rule 10b5-1 plan.

Summary

• Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics Inc. (DGX), reported a planned transaction.
• The filing details a future sale of 1,975 shares of Quest Diagnostics common stock.
• This transaction is scheduled to occur on August 15, 2025, at a price of $180 per share.
• The sale is being conducted pursuant to a pre-arranged Rule 10b5-1 sales plan.
• Following this planned transaction, Patrick Plewman will beneficially own 17,244 shares of Quest Diagnostics common stock.

Sentiment

Score: 5

Explanation: The filing reports a planned insider stock sale, which is generally neutral to slightly negative. However, the sale is part of a pre-arranged Rule 10b5-1 plan, mitigating concerns about opportunistic selling based on non-public information.

Positives

• The planned sale is part of a pre-arranged Rule 10b5-1 sales plan, indicating it was scheduled in advance and not a reaction to recent company performance or non-public information.

Negatives

• An insider, the SVP for Diagnostic Services, is planning to sell a portion of their common stock holdings.

Risks

• Potential for market misinterpretation of insider selling, despite the Rule 10b5-1 plan, though the impact is likely minimal given the transaction size and pre-planned nature.

Future Outlook

The filing details a future planned stock sale by an executive, but does not provide a broader future outlook or guidance for the company's performance.

Management Comments

• The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.

Comparison to Industry Standards

• Not applicable as this filing reports an individual insider stock transaction, not company performance metrics for industry comparison.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, though the 10b5-1 plan and relatively small transaction size lessen this impact.

Next Steps

• Execution of the planned sale of 1,975 common shares on August 15, 2025.

Key Dates

Recommendation

This Form 4 reports a pre-scheduled sale of a relatively small number of shares by an executive under a Rule 10b5-1 plan. Such transactions are common for personal financial planning and typically do not reflect a change in the company's fundamental prospects or warrant a change in investment strategy.

Keywords

Quest Diagnostics, DGX, insider trading, Form 4, stock sale, Patrick Plewman, 10b5-1 plan, common stock